Junjie Li, MD, associate chief physician at Fudan University Shanghai Cancer Center, Shanghai, China, talks with Saba Shaikh, MD, about the HER2-directed antibody-drug conjugate SHR-A1811 in the neoadjuvant treatment of HER2-positive early breast cancer.